Parkinson's Disease Studies

Pilot Clinical Studies and Development Pathway

Pilot clinical studies have been conducted across four neurological conditions to evaluate feasibility, observational outcomes, and potential directions for further clinical research.

OVERVIEW

Parkinson's Disease Studies

Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting more than 10 million people worldwide. It is characterized by motor symptoms such as tremor, rigidity, bradykinesia (slowness of movement), and impaired balance, as well as non-motor symptoms including sleep disturbance, fatigue, cognitive impairment, and mood changes. Current therapies—including levodopa and deep brain stimulation—primarily focus on symptom control rather than addressing the broader physiological dysfunction associated with the disease.

Several pilot clinical studies have explored whether biophoton-based therapies may influence neurological function, microcirculation, and regenerative processes in individuals with Parkinson’s disease. The following sections summarize the findings reported in the published studies.

Published Parkinson’s Disease Pilot Studies

EEG Study of Brain Functional Recovery in Parkinson’s Disease

One clinical study evaluated brain activity changes in individuals with Parkinson’s disease using quantitative electroencephalography (qEEG) and event-related potential (ERP) analysis before and after exposure to biophoton therapy.

The investigators measured several electrophysiological markers associated with neurological health, including posterior dominant alpha frequency, theta/beta ratio, frontal alpha asymmetry, eyes-closed/eyes-open alpha ratio, and ERP latency responses. These parameters are widely used in neuroscience to assess cognitive processing speed, attentional control, emotional regulation, and neural network stability.

After several weeks of therapy, the study reported measurable improvements in multiple EEG biomarkers. These included:

• Increased posterior alpha peak frequency, suggesting improved cortical alertness and neural synchronization.

• Reduction of the theta/beta ratio, which is often associated with better attentional control and cognitive processing.

• Improvement in frontal alpha asymmetry, indicating better emotional regulation and reduced depressive tendencies.

• Faster ERP responses, reflecting more efficient sensory and cognitive processing pathways.

The authors reported that these changes suggested improved brain network function and neurophysiological stability in the participants with Parkinson’s disease. 

Microvascular and Live-Blood Analysis Study

Another study investigated the effect of biophoton exposure on microcirculation and blood properties in individuals with Parkinson’s disease using live-blood analysis and microvascular imaging.

The study monitored blood flow characteristics and cellular morphology before treatment and after repeated exposures. Observations included improvements in red blood cell distribution, reduced cell aggregation, and more uniform microvascular circulation patterns after approximately 12 days of treatment.

These changes were interpreted by the authors as improvements in blood fluidity and microcirculatory flow. Because impaired microcirculation and oxidative stress are frequently observed in neurodegenerative diseases, improved blood flow could potentially contribute to better oxygen and nutrient delivery to neural tissues. 

Clinical Observational Study in Parkinson’s Patients

A clinical observational report described symptom changes in individuals with Parkinson’s disease during extended use of biophoton therapy devices.

Participants reported improvements in several areas commonly affected in Parkinson’s disease, including:

• Reduced tremor severity

• Improved sleep quality

• Better mobility and daily functioning

• Increased energy and reduced fatigue

The study suggested that these improvements may reflect broader changes in neurological regulation, mitochondrial energy metabolism, and autonomic nervous system balance. 

Stem Cell Mobilization Study Relevant to Neurodegeneration

Although not limited specifically to Parkinson’s disease, a randomized placebo-controlled clinical study investigated whether biophoton exposure influences circulating stem and progenitor cell populations.

The study reported significant increases in several regenerative cell populations after two weeks of exposure, including:

• CD34⁺ stem cells increased approximately 2.7-fold

• CD133⁺ stem cells increased approximately 3.5-fold

• Dual CD34⁺/CD133⁺ progenitor cells increased more than threefold

These regenerative cell populations are known to contribute to tissue repair, vascular regeneration, and neuroprotective processes. The authors suggested that such changes may represent one potential mechanism through which biophoton therapy could support recovery or resilience in chronic neurological disorders, including Parkinson’s disease.

Same Height Control

Emerging Scientific Signals

Across the Parkinson’s disease publications, several recurring findings appear:

Neurophysiological improvements

Changes in EEG biomarkers suggest improved brain network synchronization and cognitive processing.

Microcirculatory improvements

Live-blood and microvascular observations suggest better blood fluidity and circulation.

Functional improvements

Participants reported improvements in sleep, energy, and mobility.

Regenerative signals

Independent clinical data show increases in circulating stem cell populations associated with tissue repair.

Together, these early findings suggest that biophoton-based interventions may influence multiple physiological systems relevant to neurodegenerative disease, including neuronal signaling, vascular function, and regenerative processes.

Same Height Control

Implications for Future Research

The published Parkinson’s disease studies represent early pilot investigations with small sample sizes. While the findings are encouraging, larger controlled clinical trials are necessary to confirm the therapeutic potential and determine optimal treatment protocols.

Future research directions may include:

• Randomized controlled trials evaluating motor and cognitive outcomes

• Longitudinal EEG and neuroimaging studies

• Biomarker studies investigating mitochondrial function and neuroinflammation

• Multi-center clinical studies evaluating long-term safety and efficacy

Conclusion

The current published pilot studies provide preliminary evidence suggesting that biophoton therapy may influence neurological function, microcirculation, and regenerative processes in individuals with Parkinson’s disease. Reported findings include improvements in EEG biomarkers, blood microcirculation, patient-reported symptoms, and stem cell mobilization.

While additional large-scale clinical trials are required to confirm these findings, the existing studies provide an early scientific foundation for further investigation into biophoton-based approaches for neurodegenerative disorders such as Parkinson’s disease.

Disclaimer: BrainHealing.com provides informational content regarding investigational neurological treatment programs and related scientific development activities. The information presented on this website is intended for investors, researchers, healthcare professionals, and potential strategic partners.

The investigational programs described on this website are under evaluation and are not offered for commercial sale. Statements on this website should not be interpreted as claims of regulatory approval, medical efficacy, or therapeutic effectiveness unless explicitly stated.

Nothing on this website constitutes medical advice. Individuals should consult qualified healthcare professionals regarding medical conditions or treatment decisions.